Cardiac rehabilitation remains the 'Cinderella'of treatments for heart failure. This state-of-the-
art review provides a contemporary update on the evidence base, clinical guidance, and …

The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial
inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction …

Empagliflozin (Jardiance®), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) initially
developed to treat type 2 diabetes mellitus (T2DM), has also been approved in the EU and …

Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Chronic heart failure is a terminal point of a vast majority of cardiac or extracardiac causes
affecting around 1–2% of the global population and more than 10% of the people above the …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful
drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced …

Aims Current guidelines recommend that disease-modifying pharmacological therapies may
be considered for patients who have heart failure with mildly reduced ejection fraction …

Abstract According to the 202 1 European Society of Cardiology guidelines, the four pillars
of medical therapy in heart failure with reduced ejection fraction (HFrEF) include sodium …

Major international practice guidelines recommend the use of a combination of 4 medication
classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) …

The significant morbidity and mortality associated with heart failure with reduced (HFrEF) or
preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. The nitric …